Janus Henderson Group PLC Biotechnology

Janus Henderson Group PLC

$174 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
AVXL Anavex Life Sciences Corp.	$993M	$317,000 0.0% of portfolio	37,000	Q1 2025 New
NRIX Nurix Therapeutics, Inc.	$544M	$311,000 0.0% of portfolio	26,200	Q2 2024 New
IOVA Iovance Biotherapeutics, Inc.	$519M	$304,000 0.0% of portfolio	91,341	Q2 2024 Reduced 1.22%
XNCR Xencor Inc	$552M	$255,000 0.0% of portfolio	23,986	Q2 2024 Reduced 1.26%
RCUS Arcus Biosciences, Inc.	$712M	$243,000 0.0% of portfolio	31,038	Q1 2025 Added 72.07%
VIR Vir Biotechnology, Inc.	$764M	$240,000 0.0% of portfolio	37,057	Q2 2024 Reduced 1.22%
PRTA Prothena Corp Public LTD CO	$314M	$223,000 0.0% of portfolio	18,047	Q3 2024 Reduced 98.24%
ABUS Arbutus Biopharma Corp	$486M	$212,000 0.0% of portfolio	60,900	Q3 2024 New
IBRX Immunity Bio, Inc.	$1.2B	$180,000 0.0% of portfolio	59,840	Q2 2024 Reduced 1.13%
COGT Cogent Biosciences, Inc.	$802M	$174,000 0.0% of portfolio	29,073	Q4 2024 Added 84.32%
REPL Replimune Group, Inc.	$153M	$172,000 0.0% of portfolio	17,741	Q2 2024 Reduced 1.25%
DAWN Day One Biopharmaceuticals, Inc.	$530M	$168,000 0.0% of portfolio	21,300	Q1 2025 Reduced 98.37%
CRMD Cor Medix Inc.	$480M	$165,000 0.0% of portfolio	26,900	Q1 2025 New
ARVN Arvinas, Inc.	$420M	$164,000 0.0% of portfolio	23,365	Q2 2024 Reduced 27.95%
KURA Kura Oncology, Inc.	$433M	$164,000 0.0% of portfolio	24,922	Q2 2024 Reduced 1.35%
ALT Altimmune, Inc.	$201M	$160,000 0.0% of portfolio	32,000	Q2 2024 New
CAPR Capricor Therapeutics, Inc.	$163M	$155,000 0.0% of portfolio	16,400	Q4 2024 New
EYPT Eye Point Pharmaceuticals, Inc.	$357M	$144,000 0.0% of portfolio	26,700	Q2 2024 Reduced 0.58%
CGEM Cullinan Oncology, Inc.	$380M	$140,000 0.0% of portfolio	18,528	Q2 2024 New
NUVB Nuvation Bio Inc.	$545M	$134,000 0.0% of portfolio	76,700	Q2 2024 New
STOK Stoke Therapeutics, Inc.	$533M	$125,000 0.0% of portfolio	18,900	Q2 2024 New
SVRA Savara Inc	$291M	$117,000 0.0% of portfolio	42,400	Q4 2024 Reduced 82.75%
MRVI Maravai Lifesciences Holdings, Inc.	$356M	$107,000 0.0% of portfolio	48,498	Q2 2024 Reduced 1.15%
ERAS Erasca, Inc.	$209M	$100,000 0.0% of portfolio	73,200	Q4 2024 Reduced 98.22%
RLAY Relay Therapeutics, Inc.	$442M	$96,000 0.0% of portfolio	36,873	Q2 2024 Reduced 1.26%
SANA Sana Biotechnology, Inc.	$976M	$95,000 0.0% of portfolio	56,760	Q2 2024 Added 88.09%
ATXS Astria Therapeutics, Inc.	$99.9M	$94,000 0.0% of portfolio	17,700	Q4 2024 New
ORIC Oric Pharmaceuticals, Inc.	$457M	$81,000 0.0% of portfolio	14,600	Q4 2024 New
VERV Verve Therapeutics, Inc.	$667M	$68,000 0.0% of portfolio	15,031	Q2 2024 Reduced 1.67%
ANNX Annexon, Inc.	$121M	$66,000 0.0% of portfolio	34,500	Q4 2024 New
HUMA Humacyte, Inc.	$275M	$63,000 0.0% of portfolio	36,900	Q3 2024 New
PLRX Pliant Therapeutics, Inc.	$77.4M	$23,000 0.0% of portfolio	17,251	Q2 2024 Reduced 1.57%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	21,600	Q2 2024 Reduced 0.98%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.